The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Slideshows|January 17, 2020
Rheumatoid Arthritis Quiz: Does Family History Predict RA Risk?
Author(s)Katie Robinson
How strong is the familial link in rheumatoid arthritis? The answer may surprise you. Test your knowledge in this quiz.
Advertisement
How strong is the familial link in rheumatoid arthritis? The answer may surprise you. Test your knowledge in this quiz.
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement